RecruitingPhase 4NCT05743400
Thymoglobulin® Pharmacokinetics in Patients Undergoing Hematopoietic Stem Cell Transplantation
Studying Thrombotic microangiopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hospices Civils de Lyon
- Intervention
- Thymoglobulin 25 milligrams (mg) Injection(drug)
- Enrollment
- 35 target
- Eligibility
- 2 years · All sexes
- Timeline
- 2023 – 2025
Study locations (2)
- Institut d'Hématologie et d'Oncologie Pédiatrique, Lyon, France
- Centre Hospitalier Lyon Sud, Pierre-Bénite, France
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05743400 on ClinicalTrials.govOther trials for Thrombotic microangiopathy
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07059026Thrombotic Microangiopathy (TMA) Associated With Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Adult PatientsITAC (Instituto de Trasplantes y Alta Complejidad)
- RECRUITINGNCT06102694Identification of Plasma Biomarkers for Early Diagnosis of Transplant-associated Thrombotic MicroangiopathyInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGNCT06759961Post-transplant Thrombotic Microangiopathy: Evaluation of Outcomes at the Bologna Kidney Transplant CentreIRCCS Azienda Ospedaliero-Universitaria di Bologna
- ACTIVE NOT RECRUITINGPHASE3NCT04543591Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell TransplantAlexion Pharmaceuticals, Inc.